Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

June 30, 2015

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

Tarceva plus AT-101

"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ascenta Therapeutics

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT00934076 - Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter